1. Search Result
Search Result
Results for "

cyclophilin

" in MedChemExpress (MCE) Product Catalog:

88

Inhibitors & Agonists

1

Fluorescent Dye

102

Peptides

13

Natural
Products

13

Recombinant Proteins

3

Isotope-Labeled Compounds

4

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-138294
    RAS/RAS-RAF-IN-1
    1 Publications Verification

    Ras Raf Cancer
    RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity .
    RAS/RAS-RAF-IN-1
  • HY-153346

    Ras ERK Apoptosis Cancer
    RMC-6291 is an orally active and covalent inhibitor of KRAS G12C(ON). RMC-6291 forms a tri-complex within tumor cells between KRAS G12C(ON) and cyclophilin A (CypA). Thus, RMC-6291 prevents KRAS G12C(ON) from signaling via steric blockade of RAS effector binding. RMC-6291 inhibits ERK signaling and induced apoptosis in KRASG12C-mutant H358 cells. RMC-6291 also inhibits the proliferation of KRAS G12C mutant cells with a median IC50 of 0.11 nM .
    RMC-6291
  • HY-112712

    HCV Infection
    Cyclophilin inhibitor 1 is a potent and orally bioavailable cyclophilin A inhibitor, with a Kd of 5 nM, shows effective anti-HCV activity, with an EC50 of 98 nM for HCV 2a .
    <em>Cyclophilin</em> inhibitor 1
  • HY-146648

    HCV Infection
    Cyclophilin inhibitor 3 (compound 7c) is a potent cyclophilin A (CypA) inhibitor with an potent anti-HCV activity (EC50 of 4.2 μM) .
    <em>Cyclophilin</em> inhibitor 3
  • HY-125182

    HCV Infection
    SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC50 of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC50s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction .
    SMCypI C31
  • HY-157088

    Caspase Apoptosis Others
    C105SR is a cyclophilin D (CypD) inhibitor targeting to peptidyl-prolylcis-trans isomerase (PPIase). C105SR inhibits mitochondrial permeability transition opening (mPTP) with an IC 50 of 5 nM. C105SR inhibits hypoxia and reoxygenation inudced hepatocyte apoptosis and increases the level of calcium retention capacity (CRC). C105SR exhibits hepaprotective effect in ischaemia-reperfusion injury (IRI) mouse model .
    C105SR
  • HY-151487

    Sirtuin Neurological Disease Metabolic Disease Cancer
    CypD-IN-3 is a potent and subtype-selective cyclophilin D (CypD) inhibitor. CypD-IN-3 has CypD affinity with an IC50 value of 0.01 μM. CypD-IN-3 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes .
    CypD-IN-3
  • HY-151488

    Sirtuin Neurological Disease Metabolic Disease Cancer
    CypD-IN-4 is a potent and subtype-selective cyclophilin D (CypD) inhibitor. CypD-IN-4 has CypD affinity with an IC50 value of 0.057 μM. CypD-IN-4 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes .
    CypD-IN-4
  • HY-P3351

    HCV Infection
    ASP5286 is a novel non-immunosuppressive cyclophilin inhibitor for the research of HCV.
    ASP5286
  • HY-151489

    Sirtuin Neurological Disease Metabolic Disease Cancer
    CypD-IN-1 is a potent and subtype-selective cyclophilin E (CypE) inhibitor. CypD-IN-1 has CypE affinity with IC50 and Ki values of 0.013 μM and 0.072 μM, respectively. CypD-IN-1 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes .
    CypE-IN-1
  • HY-12559
    Alisporivir
    10+ Cited Publications

    Debio-025; DEB-025

    HCV Infection
    Alisporivir (Debio-025) is a cyclophilin inhibitor molecule with potent anti-hepatitis C virus (HCV) activity.
    Alisporivir
  • HY-P1354

    Calcineurin Others
    Cyclosporin A-Derivative 2 is a novel derivative from cyclosporin A. Cyclosporin A is an immunosuppressive agent which can bind to the cyclophilin and inhibit calcineurin.
    Cyclosporin A-Derivative 2
  • HY-107635
    TMN355
    1 Publications Verification

    Others Cardiovascular Disease
    TMN355 is a potent chemical cyclophilin A inhibitor and reduces foam cell formation and cytokine secretion. TMN355 is used for atherosclerosis .
    TMN355
  • HY-100731

    Cyclosporin is a cyclic decapeptide that could be isolated form the soil fungi Tolypocladium inflatum. Cyclosporin is an immunosuppressant thought to bind to cyclophilin in T-lymphocytes .
    Cyclosporin
  • HY-P1355

    Calcineurin Inflammation/Immunology
    Cyclosporin A-Derivative 1 is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1. Cyclosporin A is an immunosuppressive agent which can bind to the cyclophilin and inhibit calcineurin.
    Cyclosporin A-Derivative 1
  • HY-W039943

    Molecular Glues Cancer
    Acetyl-cyclosporin A aldehyde is an acetylated Cyclosporin A (HY-B0579) derivative with a reducing aldehyde group. Cyclosporin A is a potent calmodulin inhibitor and cyclophilin binder that can target the nuclear translocation of NF-AT and cause mitochondrial damage.
    Acetyl-cyclosporin A aldehyde
  • HY-155172

    Others Cancer
    ZX-J-19j (Compound ZX-J-19j) is a cyclophilin J inhibitor. ZX-J-19j showes potent antitumor activity .
    ZX-J-19j
  • HY-P1355A

    Calcineurin Others
    Cyclosporin A-Derivative 1 (Free base) is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1. Cyclosporin A is an immunosuppressive agent which can bind to the cyclophilin and inhibit calcineurin.
    Cyclosporin A-Derivative 1 Free base
  • HY-P0025
    NIM811
    5+ Cited Publications

    (Melle-4)cyclosporin; SDZ NIM811

    Mitochondrial Metabolism HCV Infection Inflammation/Immunology
    NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally bioavailable mitochondrial permeability transition and cyclophilin dual inhibitor, which exhibits potent in vitro activity against hepatitis C virus (HCV) .
    NIM811
  • HY-B0579S

    Cyclosporine A-d4; Ciclosporin A-d4; CsA-d4

    Antibiotic Complement System Phosphatase Inflammation/Immunology Cancer
    Cyclosporin A-d4 is the deuterium labeled Cyclosporin A. Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of calcineurin with an IC50 of 5 nM. Cyclosporin A also inhibits CD11a/CD18 ad
    Cyclosporin A-d4
  • HY-135644

    CRV431

    Sirtuin Cancer
    Rencofilstat (CRV431) is a pan-cyclophilin inhibitor with IC50 values of 2.5 nM, 3.1 nM, 2.8 nM, 7.3 nM for Cyp A, CypB, Cyp D and Cyp G, respectively. Rencofilstat reduces fibrosis and tumor growth in models of chronic liver disease .
    Rencofilstat
  • HY-B0579
    Cyclosporin A
    Maximum Cited Publications
    97 Publications Verification

    Cyclosporine A; Ciclosporin A; CsA

    Molecular Glues Phosphatase Complement System Antibiotic Inflammation/Immunology Cancer
    Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM . Cyclosporin A also inhibits CD11a/CD18 adhesion .
    Cyclosporin A
  • HY-128382

    E 151

    Enterovirus Infection
    Brilliant black BN (E151) is an azo dye and a food colorant . Brilliant black BN is a promising antiviral agent against EV71 infection via inhibiting the interaction between EV71 and its cellular uncoating factor cyclophilin A. Brilliant black BN has the potential for the investigation of contagious disease .
    Brilliant Black BN
  • HY-N1511
    Ganoderic acid D
    1 Publications Verification

    Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells . Ganoderic acid D induces HeLa human cervical carcinoma apoptosis .
    Ganoderic acid D
  • HY-B0579S2

    Cyclosporine A acetate-d4; Ciclosporin A acetate-d4; CsA acetate-d4

    Isotope-Labeled Compounds Calcineurin Inflammation/Immunology
    Cyclosporin A acetate-d4 (Cyclosporine A acetate-d4; Ciclosporin A acetate-d4) is a deuterium labeled Cyclosporin A (HY-B0579) . Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM . Cyclosporin A also inhibits CD11a/CD18 adhesion .
    Cyclosporin A acetate-d4
  • HY-B0579S3

    Cyclosporine A-13C2,d4; Ciclosporin A-13C2,d4; CsA-13C2,d4

    Isotope-Labeled Compounds Calcineurin Inflammation/Immunology
    Cyclosporin A- 13C2,d4 (Cyclosporine A- 13C2,d4; Ciclosporin A- 13C2,d4) is a 13C labeled Cyclosporin A (HY-B0579) . Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM . Cyclosporin A also inhibits CD11a/CD18 adhesion .
    Cyclosporin A-13C2,d4
  • HY-P0031
    Cyclo(RADfK)
    1 Publications Verification

    Integrin Others
    Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.
    <em>Cyclo</em>(RADfK)
  • HY-101402

    Cyclo(histidyl-proline); Histidylproline diketopiperazine

    NF-κB Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Cyclo(his-pro) (Cyclo(histidyl-proline)) is an orally active cyclic dipeptide structurally related to tyreotropin-releasing hormone . Cyclo(his-pro) could inhibit NF-κB nuclear accumulation. Cyclo(his-pro) can cross the brain-blood-barrier and affect diverse inflammatory and stress responses .
    <em>Cyclo</em>(his-pro)
  • HY-P0023
    Cyclo(-RGDfK)
    5+ Cited Publications

    Integrin Cancer
    Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
    <em>Cyclo</em>(-RGDfK)
  • HY-P0231
    AZP-531
    2 Publications Verification

    GHSR Metabolic Disease Endocrinology
    AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight.
    AZP-531
  • HY-P1934
    Cyclo(Phe-Pro)
    4 Publications Verification

    Cyclo(phenylalanylprolyl); A-64863

    HCV Infection
    Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)), a Vibrio vulnificus quorum-sensing molecule, inhibits retinoic acid-inducible gene-I (RIG-I) polyubiquitination, through its specific interaction with RIG-I, to blunt IRF-3 activation and type-I IFN production. Cyclo(Phe-Pro) (Cyclo(phenylalanylprolyl)) enhances susceptibility to hepatitis C virus (HCV), as well as Sendai and influenza viruses .
    <em>Cyclo</em>(Phe-Pro)
  • HY-126810A

    Fungal Infection
    NP213 TFA is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 TFA targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 TFA is effective and well-tolerated in resolving nail fungal infections .
    NP213 TFA
  • HY-P0023A
    Cyclo(-RGDfK) TFA
    5+ Cited Publications

    Integrin Cancer
    Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
    <em>Cyclo</em>(-RGDfK) TFA
  • HY-126810

    Fungal Infection
    NP213 is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 is effective and well-tolerated in resolving nail fungal infections .
    NP213
  • HY-107245
    Segetalin B
    1 Publications Verification

    Estrogen Receptor/ERR Metabolic Disease
    Segetalin B, a cyclopentapeptide from Vaccaria segetalis, possesses estrogen-like activity .
    Segetalin B
  • HY-P1934A

    Fungal IFNAR Reactive Oxygen Species Infection Inflammation/Immunology Cancer
    Cyclo(L-Phe-L-Pro), isolated from Pseudomonas fluorescens and Pseudomonas alcaligenes cell-free culture supernatants is an antifungal cyclic dipeptide . Cyclo(L-Phe-L-Pro) inhibits IFN-β production by interfering with retinoic-acid-inducible gene-I (RIG-I) activation . Cyclo(L-Phe-L-Pro) exhibits free-radical scavenging activity with the IC50 of 24 µM in the DPPH assay .
    <em>Cyclo</em>(L-Phe-L-Pro)
  • HY-P2300

    Cyclo(RGDfC)

    Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .
    <em>Cyclo</em>(Arg-Gly-Asp-D-Phe-Cys)
  • HY-P1938

    Bacterial Infection
    Cyclo(L-Pro-L-Val) is a 2,5-diketopiperazine, with toxic activity against phytopathogenic microorganisms (such as R. fascians LMG 3605). Cyclo(L-Pro-L-Val) shows toxicity similar to Chloramphenicol (HY-B0239) with comparable concentration. Cyclo(L-Pro-L-Val) can also inhibit gram-positive phytopathogenic bacterium. Cyclo(L-Pro-L-Val) has potential development as biopesticide .
    <em>Cyclo</em>(L-Pro-L-Val)
  • HY-P5314

    EGFR STAT Others
    OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research .
    OK2
  • HY-P1935

    Biochemical Assay Reagents Cancer
    Cyclo(Ala-Pro) is an anticancer agent that is toxic to cancer cells such as A549, HCT-116 and HepG2 .
    <em>Cyclo</em>(Ala-​Pro)
  • HY-P5038

    c(GRGDSP)

    Integrin Cancer
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) is a synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin expressed on Caco-2 cells .
    <em>Cyclo</em>(Gly-Arg-Gly-Asp-Ser-Pro)
  • HY-P5698

    Bacterial Infection
    Cyclopetide 1 (Compound 1) is an antimicrobial peptide with moderate activity against B. subtilis, with a MIC of 25 μg/mL .
    Cyclopetide 1
  • HY-P5699

    Bacterial Infection
    Cyclopetide 2 (Compound 2) is an antimicrobial peptide with moderate activity against B. subtilis, with a MIC of 50 μg/mL .
    Cyclopetide 2
  • HY-P10052

    VEGFR Cancer
    CBO-P11 specifically binds to receptor of VEGFR-2 and is used as targeting ligand for tumor angiogenesis. CBO-P11 is modified with a nearinfrared cyanine dye bearing an alkyne function, allowing both “click” coupling on azido-modified nanoparticles and fluorescence labelling .
    CBO-P11
  • HY-P10222

    HIF/HIF Prolyl-Hydroxylase Cancer
    Cyclo CRLLIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 14.5 and 10.2 μM, respectively .
    <em>Cyclo</em>(CRLLIF)
  • HY-P10223

    HIF/HIF Prolyl-Hydroxylase Cancer
    Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 65 and 123 μM, respectively .
    <em>Cyclo</em>(CRVIIF)
  • HY-P10221

    HIF/HIF Prolyl-Hydroxylase Cancer
    Cyclo CKLIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 2.6 and 2.2 μM, respectively .
    <em>Cyclo</em>(CKLIIF)
  • HY-P4820A

    Bacterial Inflammation/Immunology
    SYNV-cyclo(CGGYF) TFA is a Staphylococcus hominis (S. hominis) C5 autoinducing peptide. SYNV-cyclo(CGGYF) TFA inhibits S. aureus activity. SYNV-cyclo(CGGYF) TFA has the potential for the research of S. aureus-mediated epithelial damage and inflammation .
    SYNV-<em>cyclo</em>(CGGYF) TFA
  • HY-P4820

    Bacterial Inflammation/Immunology
    SYNV-cyclo(CGGYF) is a Staphylococcus hominis (S. hominis) C5 autoinducing peptide. SYNV-cyclo(CGGYF) inhibits S. aureus activity. SYNV-cyclo(CGGYF) has the potential for the research of S. aureus-mediated epithelial damage and inflammation .
    SYNV-<em>cyclo</em>(CGGYF)
  • HY-P3227

    XJ735

    Integrin Inflammation/Immunology
    Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective RGD peptide antagonist and has the potential for Pulmonary arterial hypertension Research .
    <em>Cyclo</em>(Ala-Arg-Gly-Asp-Mamb)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: